Relmada Therapeutics Reports $31.97 Million Net Loss and Significant Asset Growth in Latest 10-Q

Relmada Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of approximately $31.97 million for the first half of 2026, compared to a loss of $27.43 million during the same period in 2025. This resulted in a loss per share of $0.32, a decrease from $0.86 in the prior year. Total operating expenses for the six months ended June 30, 2026, were approximately $34.47 million, up from $28.44 million in the previous year, driven primarily by increased research and development costs associated with ongoing clinical trials.

In terms of financial position, Relmada's total assets surged to $219.06 million as of June 30, 2026, compared to $94.00 million at the end of 2025. This increase was largely attributed to a rise in cash and cash equivalents, which reached $11.33 million, and short-term investments, which grew to $206.40 million. The company's stockholders' equity also saw a substantial increase, rising to $206.56 million from $86.51 million at the end of the previous fiscal year, reflecting successful capital raises through stock issuances.

Strategically, Relmada has focused on enhancing its product pipeline. The company is advancing its lead candidate, NDV-01, a sustained-release formulation of gemcitabine and docetaxel, which is currently in a Phase 2 clinical trial for non-muscle invasive bladder cancer (NMIBC). Additionally, Relmada acquired sepranolone, a neurosteroid in development for Prader-Willi Syndrome and other conditions, further diversifying its portfolio. The company anticipates filing Investigational New Drug (IND) applications for both NDV-01 and sepranolone with the FDA by the end of 2026.

Operationally, Relmada's research and development expenses increased significantly, reflecting the ramp-up of clinical studies for NDV-01 and sepranolone. The company reported a total of 48 patients enrolled in the NDV-01 trial, with promising early efficacy data. The company also noted a rise in stock appreciation rights expenses, which contributed to the overall increase in operating costs. As of June 30, 2026, Relmada had 106.67 million shares outstanding, a notable increase from 73.33 million shares at the end of 2025, indicating a strategic move to bolster its capital base.

Looking ahead, Relmada remains focused on executing its clinical development strategy while managing its financial resources. The company believes its existing cash and investments will support operations for at least the next 12 months, as it continues to pursue key milestones in its clinical programs. The management's outlook emphasizes the importance of successful trial outcomes and regulatory approvals to drive future revenue generation and shareholder value.